Recently, CDK6 was found to be a direct target of MLL-fusion proteins in MLL-AF9-driven AML (Placke et al., 2014) and of infant MLL-AF4-driven ALL (Van Der Linden et al., 2014), resulting in the transcriptional activation of CDK6. The gene discussed is KMT2A; the disease is acute myeloid leukemia.